Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 March 2025 | Story Andre Damons | Photo Andre Damons
Dr Gerard Verhoef
Dr Gerard Verhoef, an intellectual property (IP) commercialisation specialist at Barnard Incorporated Attorneys, gave an oral presentation at the second Southern African Mountain Conference.

South Africa is neglecting and overlooking the economic potential of Aloe ferox, forfeiting millions in potential revenue from this ‘green gold’. In doing so, the country is denying farmers and communities the chance to prosper from the land’s true bounty and is also undermining its biodiversity.

While South Africa harvests a mere 200 tons of Aloe ferox annually, its global competitors, such as Mexico, churn out a staggering 400 000 tons of Aloe vera, says Dr Gerard Verhoef, an intellectual property (IP) commercialisation specialist at Barnard Incorporated Attorneys. He gave an oral presentation titled IKS, the public domain and Biotrade during a session on Mountain People's Livelihoods at the second Southern African Mountain Conference (SAMC2025).

Researchers, policy makers, and practitioners from across Southern Africa and beyond came together from 17 to 20 March at the scenic Champagne Sports Resort in the central Maluti-Drakensberg for SAMC2025 themed ‘Overcoming Boundaries and Barriers’.

The next rooibos

SAMC2025, under the patronage of UNESCO and organised by the University of the Free State (UFS) Afromontane Research Unit (ARU) – in partnership with the African Mountain Research Foundation (AMRF) and the Global Mountain Safeguard Research Programme (GLOMOS) – delved into critical issues around mountain ecosystems, communities, governance, and transboundary cooperation.

Aloe ferox could be the next rooibos, which is successfully using its geographical indications (GI) status to unlock value throughout the biotrade value chain, Dr Verhoef said. Other South African plants that are also an underutilised asset with economic potential for the country, include honeybush, baobab, umsuzwane, rose geranium, imphepho, Cape chamomile, Kalahari melon, mafura, sour plum, and African ginger.

A GI consists of the name of the place of origin. It links a product to a specific geographical area, which indicates the origin of where the product is produced, processed, or prepared.

Overlooking the potential of Aloe ferox, which has been scientifically proven to contain double the amino acids and 20 times more antioxidants than its international cousin, Aloe vera, Dr Verhoef explains, South Africa is not only undermining its biodiversity but also the economy. Aloe ferox is most popularly used for its laxative effect (aloe bitters) and as a topical application to the skin, eyes, and mucous membranes. It is also used for many traditional uses as well as cosmetic purposes.

Time to capitalise

According to him, Aloe ferox remains an underutilised asset, relegated to niche markets and small-scale production due to regulatory constraints and the unwillingness to obtain access and benefit-sharing (ABC) permits needed to navigate obstacles in South Africa as well as Namibia, Botswana, Zimbabwe, and Mozambique.

“This is not just an agricultural oversight; it is a glaring economic misstep. It is high time that South Africa capitalises on its green gold, turning the tables on international competitors and finally giving Aloe ferox the global podium it deserves. This is not just an agricultural oversight; it is a glaring economic misstep.

Aloe ferox could be a flagship in the global wellness market, much like rooibos has become for tea. But until we embrace and promote our indigenous resources with the same vigour as we do foreign ones, our ‘green gold’ will remain just out of reach, a latent promise unfulfilled. It’s high time South Africa capitalise and turn the tables on international competitors, finally giving Aloe ferox the global podium it deserves,” said Dr Verhoef.

The path forward, he explains, requires a radical shift in how we view and value our native species. It demands a coalition of dedicated scientists, legal advisers, and farmers to advocate for more accommodating regulations and stronger market support. The pharmaceutical and cosmetic industries – major users of aloe products – must also be brought into the fold to help recalibrate the scales in favour of Aloe ferox. South Africa’s rich biodiversity is a national treasure, yet our approach to leveraging this wealth remains timid and fragmented.

News Archive

Newly operational sequencing unit in genomics at UFS
2016-09-09

Description: Next Generation Sequencing  Tags: Next Generation Sequencing

Dr Martin Nyaga and his research assistant,
Tshidiso Mogotsi in the Next Generation
Sequencing Laboratory.
Photo: Charl Devenish

The Next Generation Sequencing (NGS) unit at the UFS was established as an interdisciplinary facility under the Directorate for Research Development, Faculty of Health Sciences and Faculty of Natural and Agricultural Sciences.

The aim of the NGS facility is to aid internal and external investigators undertaking studies on Deoxyribonucleic acid (DNA) sequencing, assembly and bioinformatics approaches using the more advanced Illumina MiSeq NGS platform.

The NGS unit became operational in 2016 and is managed by Dr Martin Nyaga and administered through the office of the Dean, Faculty of Health Sciences, under the leadership of Prof Gert Van Zyl. Dr Nyaga has vast experience in microbial genomics, having done his PhD in Molecular Virology.

He has worked and collaborated with globally recognised centres of excellence in Prokaryotic and Eukaryotic genomics, namely the J. Craig Venter Institute and the Laboratory of Viral Metagenomics, Rega Institute, among others.

The unit has undertaken several projects and successfully generated data on bacterial, viral and human genomes. Currently, work is ongoing on bacterial and fungal metagenomics studies through 16S rRNA sequencing.

In addition, the unit is also working on plasmid/insert sequencing and whole genome sequencing of animal and human rotaviruses. The unit has capacity to undertake other kinds of panels like the HLA, Pan-cancer and Tumor 15 sequencing, among others.

Several investigators from the UFS including but not limited to Prof Felicity Burt, Prof Wijnand Swart, Dr Frans O’Neil, Dr Trudi O'Neill, Dr Charlotte Boucher, Dr Marieka Gryzenhout and Dr Kamaldeen Baba are actively in collaboration with the NGS unit.

The unit has also invested in other specialised equipment such as the M220 Focused-ultrasonicator (Covaris), 2100 Bioanalyzer system (Agilent) and the real-time PCR cycler, the Rotor-Gene Q (Qiagen), which both the UFS and external investigators can use for their research.

Investigators working on molecular and related studies are encouraged to engage with Dr Nyaga on how they would like to approach their genomics projects at the UFS NGS unit. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept